207 related articles for article (PubMed ID: 28276259)
1. Effects of eldepryl on glial cell proliferation and activation in the substantia nigra and striatum in a rat model of Parkinson's disease.
Liu B; Lv C; Zhang J; Liu Y; Sun J; Cheng X; Mao W; Ma Y; Li S
Neurol Res; 2017 May; 39(5):459-467. PubMed ID: 28276259
[TBL] [Abstract][Full Text] [Related]
2. Autophagy-related protein expression in the substantia nigra and eldepryl intervention in rat models of Parkinson's disease.
Liu B; Sun J; Zhang J; Mao W; Ma Y; Li S; Cheng X; Lv C
Brain Res; 2015 Nov; 1625():180-8. PubMed ID: 26342896
[TBL] [Abstract][Full Text] [Related]
3. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Aponso PM; Faull RL; Connor B
Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
[TBL] [Abstract][Full Text] [Related]
4. [Effects of
Wang Q; Liu Z; Wang Y; Li J; Lu G; Jing Z; Liu Y; Guo Y
Zhongguo Zhen Jiu; 2018 Oct; 38(10):1093-7. PubMed ID: 30672240
[TBL] [Abstract][Full Text] [Related]
5. [Mechanism of α-lipoic acid promoting iron efflux in substantia nigra cells of Parkinson's disease rats].
Cai T; Wei C; Zhai S; Tai S; Zhang C; Jiao L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Jan; 34(1):35-40. PubMed ID: 29595455
[TBL] [Abstract][Full Text] [Related]
6. Puerarin prevents inflammation and apoptosis in the neurocytes of a murine Parkinson's disease model.
Jiang M; Yun Q; Niu G; Gao Y; Shi F; Yu S
Genet Mol Res; 2016 Oct; 15(4):. PubMed ID: 27808353
[TBL] [Abstract][Full Text] [Related]
7. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation.
Iravani MM; Leung CC; Sadeghian M; Haddon CO; Rose S; Jenner P
Eur J Neurosci; 2005 Jul; 22(2):317-30. PubMed ID: 16045485
[TBL] [Abstract][Full Text] [Related]
8. Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease.
Steiner B; Winter C; Hosman K; Siebert E; Kempermann G; Petrus DS; Kupsch A
Exp Neurol; 2006 Jun; 199(2):291-300. PubMed ID: 16360152
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
10. MPP(+) injection into rat substantia nigra causes secondary glial activation but not cell death in the ipsilateral striatum.
Canudas AM; Friguls B; Planas AM; Gabriel C; Escubedo E; Camarasa J; Camins A; Pallàs M
Neurobiol Dis; 2000 Aug; 7(4):343-61. PubMed ID: 10964606
[TBL] [Abstract][Full Text] [Related]
11. Cerebral alterations in a MPTP-mouse model of Parkinson's disease--an immunocytochemical study.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
J Neural Transm (Vienna); 2003 Oct; 110(10):1129-44. PubMed ID: 14523625
[TBL] [Abstract][Full Text] [Related]
12. Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson's disease.
Schlachetzki JC; Marxreiter F; Regensburger M; Kulinich A; Winner B; Winkler J
Restor Neurol Neurosci; 2014; 32(4):447-62. PubMed ID: 24604006
[TBL] [Abstract][Full Text] [Related]
13. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease.
Banati RB; Daniel SE; Blunt SB
Mov Disord; 1998 Mar; 13(2):221-7. PubMed ID: 9539333
[TBL] [Abstract][Full Text] [Related]
14. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
15. Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.
Savolainen MH; Albert K; Airavaara M; Myöhänen TT
Exp Brain Res; 2017 Jul; 235(7):2189-2202. PubMed ID: 28439627
[TBL] [Abstract][Full Text] [Related]
16. [Polyphenols from Toona sinensis seeds alleviate neuroinflammation in rats with Parkinson's disease via inhibiting p38MAPK signaling pathway].
Zhuang W; Chen C; Ma Y; Song L; Lyu E; Fu W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Sep; 35(9):794-799. PubMed ID: 31750820
[TBL] [Abstract][Full Text] [Related]
17. Effect of endurance exercise training on the expression of GFAP, S100B, and NSE in the striatum of chronic/progressive mouse model of Parkinson's disease.
Al-Jarrah MD; Jamous M
NeuroRehabilitation; 2011; 28(4):359-63. PubMed ID: 21725169
[TBL] [Abstract][Full Text] [Related]
18. Enteric GFAP expression and phosphorylation in Parkinson's disease.
Clairembault T; Kamphuis W; Leclair-Visonneau L; Rolli-Derkinderen M; Coron E; Neunlist M; Hol EM; Derkinderen P
J Neurochem; 2014 Sep; 130(6):805-15. PubMed ID: 24749759
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effects of repetitive transcranial magnetic stimulation in an animal model of Parkinson's disease.
Lee JY; Kim SH; Ko AR; Lee JS; Yu JH; Seo JH; Cho BP; Cho SR
Brain Res; 2013 Nov; 1537():290-302. PubMed ID: 23998987
[TBL] [Abstract][Full Text] [Related]
20. Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat.
Hoban DB; Connaughton E; Connaughton C; Hogan G; Thornton C; Mulcahy P; Moloney TC; Dowd E
Brain Behav Immun; 2013 Jan; 27(1):91-100. PubMed ID: 23044176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
